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An Unusual Presentation of Recurrent Squamous Cell Carcinoma
Tasneem Mohammad MD, Aaron Tisack BS, Mark Balle MD, and Joseph McGoey MD
Department of Dermatology
Henry Ford Health System, Detroit, MI

History

Clinical Photos

• A 65-year old African American male with a past medical
history of untreated prostate cancer and anal cancer status
post chemoradiation presented to dermatology due to a
nonhealing wound on the lateral right hip.
• The patient had previously undergone excision of a
cutaneous squamous cell carcinoma (cSCC) in this area,
followed by Mohs surgery due to local recurrence.
• In both procedures, clear margins were noted histologically.
• The patient noted that although the area had healed partially,
the center had not healed and he had begun to develop a
painful rash with blisters surrounding the wound

Figure 2: cSCC of the right hip
prior to Mohs surgery.

Examination
• On the right hip there was a large non-healing wound with
granulation tissue and yellow fibrinous adherent material.
• The posterior edge of the wound had grouped greyish
papules and fluctuant vesicles with serosanguinous
drainage.
• On subsequent visits the lesions were rapidly progressive.

Figure 3: Rapidly spreading grey
papules and vesicles on the right hip
with central nonhealing surgical site.

Histopathology
Course and Therapy

Figure 1: Punch biopsy of the right hip shows epidermal hyperplasia
and ulceration with atypical squamous islands invading into the dermis.

• Due to the vesicular and rapidly spreading nature of the lesion, an
infectious process was favored. However, there was no improvement
after treatment with antibiotics and antivirals.
• At follow up, progression was noted. The differential at that time
included recurrent SCC versus pyoderma gangrenosum versus
infection.
• Biopsies for H&E and for tissue culture (aerobes, anaerobes, atypical
mycobacterium, and fungi) were performed.
• There was no growth of any organisms on tissue culture.
• H&E showed features consistent with moderately differentiated SCC
with high grade features.
• After discussion at tumor board, the patient was referred to radiation
oncology, surgical oncology, and medical oncology for further
management.
• The patient refused palliative radiation, but cemiplimab, a PD-1
inhibitor, is being initiated.

Discussion
• Cutaneous SCC is the second most common type of skin
cancer with excellent outcomes after surgical removal in
most cases.
• Local recurrence is rare, occurring in about 4.6% of
tumors, but is a sign of aggressive biologic behavior.
• Clinical risk factors for recurrence/metastasis include:
–Tumor diameter >2 cm
–Immunosuppressed state
–Location on the lip or ear
–Arising in a burn or scar
• Histological risk factors for recurrence/metastasis on
pathology include:
–Perineural invasion
–Tumor depth with Breslow thickness >2 mm (10x risk)
–Poor differentiation (3x risk of well-differentiated)
–Desmoplastic SCC subtype (10x risk of recurrence)
• In cases that recurrence of squamous cell carcinoma is a
possibility, the threshold for biopsy is low even if the
clinical course is not congruent.
• A multidisciplinary approach is critical in the management
of these patients to reduce morbidity and mortality.
• Systemic therapies for advance SCC include:
–Chemotherapy (primarily platins)
–EGFR inhibitors
–PD-1 inhibitors (cemiplimab, nivolumab, and
pembrolizumab)
• Radiation continues to play a pivotal role in both curative
and palliative treatment.
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